Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens Meeting Abstract
| Authors: | Einsele, H.; Delforge, M.; Patel, K.; Eliason, L.; Dhanda, D.; Shi, L.; Guo, S.; Marshall, T.; Arnulf, B.; Cavo, M.; Nooka, A.; Manier, S.; Callander, N.; Giralt, S.; Ailawadhi, S.; McKiver, M. P.; Cook, M.; Otero, P. R. |
| Abstract Title: | Patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (TCE RRMM) patients in KarMMa 3 trial (Phase 3 RCT): Idecabtagene Vicleucel (ide-cel) versus standard regimens |
| Meeting Title: | Oncology Research and Treatment |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 46 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2023 Oct 13-16 |
| Meeting Location: | Hamburg, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2023-10-01 |
| Start Page: | 83 |
| Language: | English |
| ACCESSION: | WOS:001091456900166 |
| PROVIDER: | wos |
| PUBMED: | 37788643 |
| DOI: | 10.1159/000533576 |
| Notes: | Meeting Abstract: V545 -- Source: Wos |
